CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells

Genes and Cancer

Volumn 1, Issue 4, 2010, Pages 369-380

  Bettayeb, Karima ^a,e   Baunbæk, Dianne ^a   Delehouze, Claire ^a,f   Loaëc, Nadège ^a   Hole, Alison J ^b   Baumli, Sonja ^b   Endicott, Jane A ^c   Douc Rasy, Setha ^c   Bénard, Jean ^c   Oumata, Nassima ^d,e   Galons, Hervé ^d   Meijer, Laurent ^a  

^a Protein Phosphorylation and Human Disease Group   (France)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CNRS   (France)

^e ROCKEFELLER UNIVERSITY   (United States)

^f Centre de Perharidy   (France)

Author keywords

CR8; Cyclin dependent kinase; Mcl 1; Neuroblastoma; Roscovitine

Indexed keywords

CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR CR8; CYCLIN T; MESSENGER RNA; ONCOPROTEIN; PROTEIN MCL 1; PROTEIN MYCN; PROTEIN NOXA; PROTEIN P53; ROSCOVITINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; UPREGULATION;

EID: 79952837100     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601910369817     Document Type: Article

References (82)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nature Rev 2003;3:203-16.
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
3. Mueller S, Matthay KK. Neuroblastoma: biology and staging. Curr Oncol Rep 2009;11:431-48.
4. Van Roy N, De Preter K, Hoebeeck J, Van Maerken T, Pattyn F, Mestdagh P, et al. The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med 2009;1:74.
5. Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M. Molecular characterization and classification of neuroblastoma. Future Oncol 2009;5:625-39.
6. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-33.
7. Wagner LM, Danks MK. New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem 2009;107:46-57.
8. Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 2010;29: 1566-79.
9. Moll UM, LaQuaglia M, Bénard J, Riou G. Wild-type p53 protein undergoes nuclear exclusion in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 1995;92:4407-11.
10. Teitz T, Wei T, Valentine MB. Caspase-8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Med 2000;6:529-35.
11. Delloye-Bourgeois C, Fitamant J, Paradisi A, Cappellen D, Douc-Rasy S, Raquin MA, et al. Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med 2009;206:833-47.
12. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated in a randomized trial of myeloablative therapy followed by cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009;27:1007-13.
13. Malumbres M, Barbacid M. Cell cycle CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
14. Malumbres M, Harlow E, Hunt T, Hunter T, Lahti JM, Manning G, et al. Cyclin-dependent kinases: a family portrait. Nat Cell Biol 2009;11:1275-76.
15. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002;23:417-25.
16. Smith PJ, Yue E, editors. CDK inhibitors of cyclin-dependent kinases as anti-tumor agents: monographs on enzyme inhibitors. Boca Raton, FL: CRC Press Taylor & Francis; 2006.
17. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.
18. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008;29:16-21.
19. Galons H, Oumata N, Meijer L. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin Ther Patents 2009;20:377-404.
20. Meijer L, Borgne A, Mulner O, Chong JPJ, Blow JJ, Inagaki N, et al. Biochemical and cellular effects of roscovitine a potent and selective inhibitor of the cyclin-dependent kinases cdc2 cdk2 and cdk5. Eur J Biochem 1997;243:527-36.
21. Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors: from starfish oocytes to clinical trials. Acc Chem Res 2003;36:417-25.
22. Meijer L, Bettayeb K, Galons H. Roscovitine (CYC202, seliciclib). In: Smith PJ, & Yue E, editors. Monographs on enzyme inhibitors CDK inhibitors and their potential as anti-tumor agents. Boca Raton, FL: CRC Press Taylor & Francis; 2006. p. 187-226.
23. Aldoss IT, Tashi T, Ganti AK. Seliciclib in malignancies. Expert Opin Investig Drugs 2009;18:1957-65.
24. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96:29-37.
25. Hsieh WS, Soo R, Peh BK, Loh T, Dong D, Soh D, et al. Pharmacodynamic effects of seliciclib an orally administered cell cycle modulator in undifferentiated nasopharyngeal cancer. Clin Cancer Res 2009;15:1435-42.
26. Vita M, Abdel-Rehim M, Olofsson S, Hassan Z, Meurling L, Siden A, et al. Tissue distribution pharmacokinetics and identification of roscovitine metabolites in rat. Eur J Pharm Sci 2005;25:91-103.
27. Nutley BP, Raynaud FI, Wilson SC, Fischer PM, Hayes A, Goddard PM, et al. Metabolism and pharmacokinetics of the cyclindependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther 2005;4:125-39.
28. McClue SJ, Stuart I. Metabolism of the trisubstituted purine cyclindependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos 2008;36:561-70.
29. Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, et al. CR8 a potent and selective roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008;27:5797-807.
30. Oumata N, Bettayeb K, Ferandin Y, Demange L, Lopez-Giral A, Goddard M-L, et al. Roscovitine-derived dual-specificity inhibitors of cyclin-dependent kinases (CDKs) and casein kinase 1 (CK1). J Med Chem 2008;51:5229-42.
31. Hahntow IN, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F, et al. Cyclin-dependent kinase inhibitor roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004;18:747-55.
32. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-91.
33. Hallaert DY, Spijker R, Jak M, Derks IA, Alves NL, Wensveen FM, et al. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. Cell Death Differ 2007;14:1958-67.
34. McCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella- Borradori A, et al. Seliciclib (CYC202 R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005;65:5399-407.
35. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, et al. Seliciclib (CYC202 or R-roscovitine) a small-molecule cyclindependent kinase inhibitor mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005;106:1042-7.
36. Hui AB, Yue S, Shi W, Alajez NM, Ito E, Green SR, et al. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clin Cancer Res 2009;15:3716-24.
37. Mandelin AM II, Pope RM. Myeloid cell leukemia-1 as a therapeutic target. Expert Opin Ther Targets 2007;11:363-73.
38. Warr MR, Shore GC. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 2008;8:138-47.
39. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 2009;66:1326-36.
40. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010;463:103-7.
41. Lestini BJ, Goldsmith KC, Fluchel MN, Liu X, Chen NL, Goyal B, et al. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 2009;8:1587-95.
42. Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, et al. Inactivation of CDK2 is synthetically lethal to MYCN overexpressing cancer cells. Proc Natl Acad Sci USA 2009;106:12968-73.
43. Oumata N, Ferandin Y, Meijer L, Galons H. Practical synthesis of roscovitine and CR8. Organic Process Res Dev 2009;13:641-4.
44. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, et al. Roscovitine targets protein kinases and pyridoxal kinase. J Biol Chem 2005;280:31208-19.
45. Bain J, Plater L, Elliott M, Shapiro N, Hastie CJ, McLauchlan H, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315.
46. Behrend L, Milne DM, Stoter M, Deppert W, Campbell LE, Meek DW, et al. IC261 a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. Oncogene 2000;19:5303-13.
47. Rena G, Bain J, Elliott M, Cohen P. D4476 a cell-permeant inhibitor of CK1 suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep 2004;5:60-65.
48. Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T, et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 2004;279:24246-54.
49. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
50. Tanramluk D, Schreyer A, Pitt WR, Blundell TL. On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine. Chem Biol Drug Des 2009;74:16-24.
51. Tang L, Li MH, Cao P, Wang F, Chang WR, Bach S, et al. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 2005;280:31220-9.
52. Baumli S, Lolli G, Lowe ED, Troiani S, Rusconi L, Bullock AN, et al. The structure of P-TEFb (CDK9/cyclin T1) its complex with flavopiridol and regulation by phosphorylation. EMBO J 2008;27:1907-18.
53. Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC, et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO PS-341 and MG-132. Cancer Res 2006;66:6379-86.
54. David-Pfeuty T. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene 1999;18:7409-22.
55. Blaydes JP, Craig AL, Wallace M, Ball HM, Traynor NJ, Gibbs NK, et al. Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene 2000;19:3829-39.
56. Kotala V, Uldrijan S, Horky M, Trbusek M, Strnad M, Vojtesek B. Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases. Cell Mol Life Sci 2001;58:1333-9.
57. Lu W, Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001;20:3206-16.
58. Ljungman M, Paulsen MT. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol 2001;60:785-9.
59. Wojciechowski J, Horky M, Gueorguieva M, Wesierska-Gadek J. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 2003;106:486-95.
60. Wesierska-Gadek J, Wandl S, Kramer MP, Pickem C, Krystof V, Hajek SB. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells. J Cell Biochem 2008;105:1161-71.
61. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
62. Ribas J, Boix J, Meijer L. Roscovitine (CYC202 seliciclib) sensitizes SH-SY5Y neuroblastoma cells to Nutlin-3 induced apoptosis. Exp Cell Res 2006;312:2394-400.
63. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G arrest after DNA damage. Science 1998;282:1497-501.
64. Ploner C, Kofler R, Villunger A. Noxa: at the tip of the balance between life and death. Oncogene 2009;27:S84-S92.
65. Chen QR, Song YK, Yu LR, Wei JS, Chung JY, Hewitt SM, et al. Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma. J Proteome Res 2010;9:373-82.
66. Nevo I, Oberthuer A, Botzer E, Sagi-Assif O, Maman S, Pasmanik-Chor M, et al. Gene-expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients. Int J Cancer 2010;126:1570-81.
67. Lu X, Pearson A, Lunec J. The MYCN oncoprotein as a drug development target. Cancer Lett 2003;197:125-30.
68. Lu X, Vogt PK, Boger DL, Lunec J. Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncol Rep 2008;19:825-30.
69. Grotzer MA, Castelletti D, Fiaschetti G, Shalaby T, Arcaro A. Targeting Myc in pediatric malignancies of the central and peripheral nervous system. Curr Cancer Drug Targets 2009;9:176-88.
70. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene 2010;29:1249-59.
71. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68:3389-95.
72. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5.
73. van Maerken T, Speleman F, Vermeulen J, Lambertz I, DeClercq S, DeSmet E, et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 2006;66:9646-55.
74. Abel F, Sjöberg RM, Nilsson S, Kogner P, Martinsson T. Imbalance of the mitochondrial pro- and anti-apoptotic mediators in neuroblastoma tumours with unfavourable biology. Eur J Cancer 2005;41:635-46.
75. Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, et al. Copy number variation at 1q211 associated with neuroblastoma. Nature 2009;459:987-91.
76. Garrofé-Ochoa X, Melero-Fernández de Mera RM, FernándezGómez FJ, Ribas J, Jordán J, Boix J. BAX and BAK proteins are required for cyclin-dependent kinase inhibitory drugs to cause apoptosis. Mol Cancer Ther 2008;7:3800-6.
77. Collaborative Computational Project Number 4. The CCP4 Suite: Programs for Protein Crystallography. Acta Cryst 1994;D50:760-3.
78. Adams PD, Grosse-Kunstleve RW, Hung L-W, Ioerger TR, McCoy AJ, Moriarty NW, et al. PHENIX: building new software for automated crystallographic structure determination. Acta Cryst 2002; D58:1948-54.
79. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Cryst 2004;D60:2126-32.
80. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 2007;35(Web Server issue):W375-83.
81. Ribas J, Boix J. Cell differentiation caspase inhibition and macromolecular synthesis blockage but not BCL-2 or BCL-XL proteins protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs. Exp Cell Res 2004;295:9-24.
82. Goldschneider D, Horvilleur E, Plassa LF, Guillaud-Bataille M, Million K, Wittmer-Dupret E, et al. Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res 2006;34:5603-5612.